A comparison of two robotic platforms to screen plateletpheresis donors for HLA antibodies as part of a transfusion-related acute lung injury mitigation strategy
Ralph R. Vassallo
From the American Red Cross, Penn-Jersey Region, Philadelphia, Pennsylvania; Quality Analytics, Inc., Riverwoods, Illinois; and the Blood Components Department, American Red Cross, Holland Laboratory, Rockville, Maryland.
Search for more papers by this authorSusan Hsu
From the American Red Cross, Penn-Jersey Region, Philadelphia, Pennsylvania; Quality Analytics, Inc., Riverwoods, Illinois; and the Blood Components Department, American Red Cross, Holland Laboratory, Rockville, Maryland.
Search for more papers by this authorMindy Einarson
From the American Red Cross, Penn-Jersey Region, Philadelphia, Pennsylvania; Quality Analytics, Inc., Riverwoods, Illinois; and the Blood Components Department, American Red Cross, Holland Laboratory, Rockville, Maryland.
Search for more papers by this authorJonathan Barone
From the American Red Cross, Penn-Jersey Region, Philadelphia, Pennsylvania; Quality Analytics, Inc., Riverwoods, Illinois; and the Blood Components Department, American Red Cross, Holland Laboratory, Rockville, Maryland.
Search for more papers by this authorJaye Brodsky
From the American Red Cross, Penn-Jersey Region, Philadelphia, Pennsylvania; Quality Analytics, Inc., Riverwoods, Illinois; and the Blood Components Department, American Red Cross, Holland Laboratory, Rockville, Maryland.
Search for more papers by this authorGary Moroff
From the American Red Cross, Penn-Jersey Region, Philadelphia, Pennsylvania; Quality Analytics, Inc., Riverwoods, Illinois; and the Blood Components Department, American Red Cross, Holland Laboratory, Rockville, Maryland.
Search for more papers by this authorRalph R. Vassallo
From the American Red Cross, Penn-Jersey Region, Philadelphia, Pennsylvania; Quality Analytics, Inc., Riverwoods, Illinois; and the Blood Components Department, American Red Cross, Holland Laboratory, Rockville, Maryland.
Search for more papers by this authorSusan Hsu
From the American Red Cross, Penn-Jersey Region, Philadelphia, Pennsylvania; Quality Analytics, Inc., Riverwoods, Illinois; and the Blood Components Department, American Red Cross, Holland Laboratory, Rockville, Maryland.
Search for more papers by this authorMindy Einarson
From the American Red Cross, Penn-Jersey Region, Philadelphia, Pennsylvania; Quality Analytics, Inc., Riverwoods, Illinois; and the Blood Components Department, American Red Cross, Holland Laboratory, Rockville, Maryland.
Search for more papers by this authorJonathan Barone
From the American Red Cross, Penn-Jersey Region, Philadelphia, Pennsylvania; Quality Analytics, Inc., Riverwoods, Illinois; and the Blood Components Department, American Red Cross, Holland Laboratory, Rockville, Maryland.
Search for more papers by this authorJaye Brodsky
From the American Red Cross, Penn-Jersey Region, Philadelphia, Pennsylvania; Quality Analytics, Inc., Riverwoods, Illinois; and the Blood Components Department, American Red Cross, Holland Laboratory, Rockville, Maryland.
Search for more papers by this authorGary Moroff
From the American Red Cross, Penn-Jersey Region, Philadelphia, Pennsylvania; Quality Analytics, Inc., Riverwoods, Illinois; and the Blood Components Department, American Red Cross, Holland Laboratory, Rockville, Maryland.
Search for more papers by this authorAbstract
BACKGROUND: Efforts to minimize white blood cell alloantibodies, responsible for transfusion-related acute lung injury (TRALI) in components with high-volume single-donor plasma include consideration of plateletpheresis donor screening for human leukocyte antigen (HLA) antibodies. High-throughput screening platforms make this feasible for large blood centers. Which platform to use, donor subgroups to screen, characteristics of detected antibodies, and operational impact of deferring reactive donors are important questions.
STUDY DESIGN AND METHODS: We screened 2462 plateletpheresis donor sera for HLA antibodies on automated instruments using HLA Class I and II enzyme-linked immunosorbent assays (ELISA) or a mixed Class I/II Luminex flow analyzer. Screen-reactive samples were further tested by manual Luminex single-antigen assay to determine antibody specificity, estimated corresponding antigen frequency, and signal strength.
RESULTS: Alloexposed females had the highest reactivity rate on both platforms (21.0%), with much lower rates for nonexposed individuals or transfused males (1.4%-5.4%). Increasing parity and more recent pregnancy increased their likelihood of screen reactivity. Deferring screen-reactive parous females would result in at least a 4.8% plateletpheresis donor base decrement. Supplemental testing showed higher rates of nonspecific or natural antibodies in ELISA screen-reactive alloexposed females (2.5%) than Luminex (0%). Both assays were more likely to identify antibodies directed against a larger number of HLA antigens and/or of presumed higher titer in alloexposed donors.
CONCLUSION: A strategy screening only parous female donors is reasonable. Both automated HLA antibody detection platforms are easy to use and preferentially identify alloexposed individuals with antibodies of presumed higher titer directed against more recipient HLA antigens.
REFERENCES
- 1 Eder AF, Herron R, Strupp A, Dy B, Notari EP, Chambers LA, Dodd RY, Benjamin RJ. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion 2007; 47: 599-607.
- 2 Toy P, Popovsky MA, Abraham E, Ambruso DR, Holness LG, Kopko PM, McFarland JG, Nathens AB, Silliman CC, Stroncek D; National Heart, Lung and Blood Institute Working Group on TRALI. Transfusion-related acute lung injury: definition and review. Crit Care Med 2005; 33: 721-6.
- 3 Kleinman S, Caulfield T, Chan P, Davenport R, McFarland J, McPhedran S, Meade M, Morrison D, Pinsent T, Robillard P, Slinger P. Toward an understanding of transfusion-related lung injury: statement of a consensus panel. Transfusion 2004; 44: 1774-89.
- 4 Triulzi D. Transfusion-related acute lung injury: current concepts for the clinician. Anesth Analg 2009; 108: 770-6.
- 5 Popovsky MA, Abel MD, Moore SB. Transfusion-related acute lung injury associated with passive transferred antileukocyte antibodies. Am Rev Respir Dis 1983; 128: 185-9.
- 6 Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985; 25: 573-7.
- 7 Stillman CC, McLaughlin NJ. Transfusion-related acute lung injury. Blood Rev 2006; 20: 139-59.
- 8 Bux J, Becker F, Seeger W, Kilpatrick D, Chapman J, Waters A. Transfusion-related acute lung injury due to HLA-A2-specific antibodies in recipient and NB-1 specific antibodies in donor blood. Br J Haematol 1996; 93: 707-13.
- 9 Kopko PM, Popovsky MA, Mackenzie MR, Paglieroni TG, Muto KN, Holland PV. HLA Class II antibodies in transfusion-related acute lung injury. Transfusion 2001; 41: 1244-8.
- 10 Kao GS, Wood IG, Dorfman DM, Milford EL, Benjamin RJ. Investigations into the role of anti-HLA Class II antibodies in TRALI. Transfusion 2003; 43: 185-91.
- 11 Maslanka K, Michur H, Zupanska B, Uhrynowska M, Nowak J. Leukocyte antibodies in blood donors and a look back on recipients of their blood components. Vox Sang 2007; 92: 247-9.
- 12 Davoren A, Curtis BR, Shulman IA, Mohrbacher AF, Bux J, Kwiatkowska BJ, McFarland JG, Aster RH. TRALI due to granulocyte-agglutinating human neutrophil antigen—3a (5b) alloantibodies in donor plasma: a report of 2 fatalities. Transfusion 2003; 43: 641-5.
- 13 Toy P, Sun J, Hollis-Perry M, Jun J, Nakagawa M. Recipients of blood from a donor with multiple HLA antibodies. A blinded, lookback study of TRALI. Transfusion 2004; 44: 1683-8.
- 14 Munitz M, Sheldon S, Schuller RM, Young NS, Klein HG, Leitman SF, Stroncek DF. Patient-specific transfusion-related acute lung injury. Vox Sang 2008; 94: 70-3.
- 15 Zupanska B, Uhrynowska M, Michur H, Maslanka K, Zajko M. Transfusion-related acute lung injury and leukocyte-reacting antibodies. Vox Sang 2007; 93: 70-7.
- 16 Popovsky MA, Haley NR. Further characterization of transfusion-related acute lung injury: demographics, clinical and laboratory features, and morbidity. Immunohematology 2000; 16: 157-9.
- 17 Win N, Massey E, Lucas G, Sage D, Brown C, Green A, Contreras M, Navarrete C. Ninety-six suspected transfusion related acute lung injury cases: investigation findings and clinical outcome. Hematology 2007; 12: 461-9.
- 18 Stainsby D, Jones H, Knowles S, Chapman C, Davison K, Gray A, Cohen H, Boncinelli A, Birchall J, Milkins C, Brant L. Serious Hazards of Transfusion, 2004 Annual Report [cited 2010 Feb 25]. Available from: URL: http://www.shot-uk.org/SHOTREPORT2004.pdf
- 19 Sachs UJ, Link E, Hofmann C, Wasel W, Bein G. Screening of multiparous women to avoid transfusion-related acute lung injury: a single centre experience. Transfus Med 2008; 18: 348-54.
- 20 Reil A, Keller-Stanislawski B, Günay S, Bux J. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang 2008; 95: 313-7.
- 21 Middleburg RA, VanStein D, Briet E, Van Der Bom JG. The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: a systematic review. Transfusion 2008; 48: 2167-76.
- 22 Stroncek DF, Fadeyi E, Adams S. Leukocyte antigen and antibody detection assays: tools for assessing and preventing pulmonary transfusion reactions. Transfus Med Rev 2007; 21: 273-86.
- 23 MacLennan S, Lucas G, Brown C, Evans R, Kallon D, Brough S, Contreras M, Navarrete C. Prevalence of HLA and HNA antibodies in donors: correlation with pregnancy and transfusion history. Vox Sang 2004; 87 Suppl 3: 4.
- 24 Triulzi D, Kakaiya R, Schreiber G. Donor risk factors for white blood cell antibodies associated with transfusion-related acute lung injury REDS II Leukocyte Antibody Prevalence Study. Transfusion 2007; 47: 563-4.
- 25 Triulzi DJ, Kleinman S, Kakaiya RM, Busch MP, Norris PJ, Steele WR, Glynn SA, Hillyer CD, Carey P, Gottschall JL, Murphy EL, Rios JA, Ness PM, Wright DJ, Carrick D, Schreiber GB for the Retrovirus Epidemiology in Donor Study II. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion 2009; 49: 1825-35.
- 26 Einarson M, Vassallo R, Moroff G, Barone J, Ponisciak M, Jakows S, Quinn M, Stearns F, Forey J, Murray C, Hsu S. HLA Class I antibody specificity in apheresis donors. Transfusion 2008; 48 Suppl: 250A.
- 27 Looney MR, Su X, Van Ziffle JA, Lowell CA, Madhay MA. Neutrophils and their Fcγ receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest 2006; 116: 1615-23.
- 28 Dykes A, Smallwood D, Kotsimbos T, Treet A. Transfusion related acute lung injury (TRALI) in a patient with a single lung transplant. Br J Haematol 2000; 109: 674-6.
- 29 AABB Association Bulletin 06-07. Transfusion-related acute lung injury, 2006 [cited 2010 Feb 25]. Available from: URL: http://www.aabb.org/Content/Members_Area/Association_Bulletins/ab06-07.htm
- 30 Gajic O, Rana R, Winters J, Yilmaz M, Mendez JL, Rickman OB, O'Byrne MM, Evenson LK, Malinchoc M, DeGoey SR, Afessa B, Hubmayr RD, Moore SB. Transfusion-related acute lung injury in the critically ill: prospective nested case control study. Am J Respir Crit Care Med 2007; 176: 886-91.
- 31 Nishimura M, Hashimoto S, Takanashi M, Okazaki H, Satake M, Nakajima K. Role on anti-human leukocyte antigen Class II alloantibody and monocytes in development of transfusion-related acute lung injury. Transfus Med 2007; 17: 129-34.
- 32 Chapman CE, Stainsby D, Jones H, Love E, Massey E, Win N, Navarrete C, Lucas G, Soni N, Morgan C, Choo L, Cohen H, Williamson LM; Serious Hazards of Transfusion Steering Group. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion 2009; 49: 440-52.
- 33 Dunn P, Dinesh D. Transfusion-related acute lung injury (TRALI): a review of investigations by the National Tissue Typing Laboratory of cases reported in New Zealand since June 2004. N Z Med J 2008; 121: 42-7.
- 34 Eder AF, Benjamin RJ. TRALI risk reduction: donor and component management strategies. J Clin Apher 2009; 24: 122-9.
- 35 Domen RE, Casey H, Gaspari J. Correlation of HLA donor specific antibody (DSA) titers with Luminex mean fluorescence intensity (MFI). Hum Immunol 2008; 69 Suppl 1: S35.
- 36 Mizutani K, Terasaki P, Hamdani E, Esquenazi V, Rosen A, Miller J, Ozawa M. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007; 7: 1027-31.
- 37 Morrales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA, Lee J, El-Awar NR, Alberu JS. “Natural” HLA antibodies in non-alloimmunized healthy males. Transplantation 2008; 86: 1111-5.
- 38 Alberu J, Morales-Buenrostro LE, De Leo C, Vargas-Rojas MI, Marino-Vazquez LA, Crispin JC. A non-allogeneic stimulus triggers the production of de novo HLA antibodies in healthy adults. Transplant Immunol 2007; 18: 166-71.
- 39 Fadeyi E, Adams S, Peterson B, Hackett J, Byrne P, Klein HG, Marincola FM, Leitman SF, Stroncek DF. Analysis of a high-throughput HLA antibody screening assay for use with platelet donors. Transfusion 2008; 48: 1174-9.
- 40 Powers A, Stowell CP, Dzik WH, Saidman SL, Lee H, Makar RS. Testing only donors with a prior history of pregnancy or transfusion is a logical and cost-effective transfusion-related acute lung injury prevention strategy. Transfusion 2008; 48: 2549-58.
- 41 Tongio MM, Falkenrodt A, Mitsuishi Y, Urlacher A, Bergerat JP, North ML, Mayer S. Natural HLA antibodies. Tissue Antigens 1985; 26: 271-85.
- 42 Sasaki N, Idica A, Terasaki PI. Mimetic human leukocyte antigen epitopes: shown by monoclonal antibodies and extra antibodies produced on transplantation. Transplantation 2008; 86: 912-8.
- 43 Cai J, Terasaki PI, Anderson N, Lachmann N, Schönemann C. Intact HLA not β2m-free heavy chain-specific HLA Class I antibodies are predictive of graft failure. Transplantation 2009; 88: 226-30.
Citing Literature
